spacer
home > ebr > autumn 2018 > rising to the challenge
PUBLICATIONS
European Biopharmaceutical Review

Rising to the Challenge

Advanced therapy medicinal products (ATMPs) represent one of the fastest-growing areas of clinical research due to their potential to cure severe chronic conditions. Despite the important health benefits that ATMPs are expected to bring, relatively few have reached the market, and several have been subsequently withdrawn. Oncology indications remain the largest sector in the UK, and, while Phase 3 trials have increased, most are still in early phase development. Therefore, it is likely to be several years before the full potential for ATMPs is translated into meaningful patient benefit and will be dependent upon researchers overcoming numerous challenges, including recruitment, operational, and safety considerations. Overcoming these challenges requires innovation, collaboration, and sound strategic development to ensure ATMPs are brought to market efficiently and without a prohibitive impact on drug budgets. This article will discuss how researchers in the UK are at the forefront of this scientific endeavour, with several exciting collaborations, backed by Innovate UK, generating optimism for future success.

The ATMP Market

ATMPs are a new generation of treatments that use gene therapy, cell therapy, and tissue engineering. They offer unprecedented promise for the treatment of diseases or injuries that currently have a high, unmet medical need, such as Alzheimer’s disease, cancer, muscular dystrophy, ophthalmology, and skin in burns victims. Given their curative potential in severe chronic conditions, ATMPs are, unsurprisingly, one of the fastest-growing areas of research, with an estimated global market opportunity of up to £14 billion by 2025, with predicted additional year-on-year growth potential of 25% to 2030.

While optimism may be justified for the future of ATMPs, the situation today is that this technology remains extremely complex and expensive and is only available to a small number of patients. Results from clinical studies have shown promise, but few products have yet to reach the market – only 10 have been approved in Europe, most recently being Alofisel (to treat anal fistulas in Crohn’s Disease) from TiGenix/Takeda. Of these, four have since been withdrawn. This is slow progress considering that the first ATMP, chondrocelect (to repair damage to the cartilage in the knee), was approved nine years ago, especially given the level of interest and investment in the field.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Fiona Thistlethwaite is a Medical Oncology Consultant within the experimental cancer medicine team at The Christie Hospital, UK, and Honorary Senior Lecturer at the Division of Cancer Sciences, Faculty of Biology Medicine & Health, at The University of Manchester, UK. Fiona is also the Director for iMATCH.

Dr Ian Thomas is a drug development expert with several decades of early and late phase oncology experience. In his role as Clinical Delivery Director for Aptus Clinical, a specialist CRO, Ian leads the company’s advanced therapy clinical development activities and is extensively involved in supporting iMATCH.
spacer
Dr Fiona Thistlethwaite
spacer
spacer
spacer
Dr Ian Thomas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Quality of Steel

Natoli Engineering Company, Inc.

Steel quality is the summation of how well a steel meets its specified chemistry, the cleanliness of the steel or degree to which it is free of impurities or inclusion, homogeneity of the microstructure, grain/carbide size and in some instances if it meets the mechanical requirements for that particular steel. In the design and manufacture of tablet compression tooling, nothing is more important than the quality of the materials being used. The best manufacturing principals maintaining the tightest tolerances will result in tool failure if the initial material quality is poor. Material quality is the fundamental building block upon which all successive value added steps are laid. The majority of all tablet compression tooling is produced from steel and steel quality is the subject of this article.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement